ImmunityBio’s Stock Surge Fueled by Rapid Regulatory Momentum

ImmunityBio is making a prominent appearance at the 38th Annual ROTH Conference this week, a move underscored by a remarkable series of recent developments. The company’s shares have recorded a staggering year-to-date gain exceeding 323%, a rally driven by significant clinical and regulatory progress for its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln).

A Trio of Catalysts: From Macau to Updated Guidelines

The company’s momentum is built on three key events occurring in close succession. On March 20, ImmunityBio secured its first Asian market approval, with Macau’s drug authority authorizing ANKTIVA in combination with BCG for bladder cancer patients unresponsive to BCG therapy alone. This approval, part of a broader push into 34 countries and territories, was granted through a recognition pathway based on prior decisions by the U.S. FDA and the European EMA.

Also on March 20, the influential National Comprehensive Cancer Network (NCCN) updated its clinical guidelines for bladder cancer. The organization now lists ANKTIVA plus BCG as a Category 2A recommendation for patients with papillary tumors without carcinoma in situ—an indication not currently on the FDA-approved label. This classification, supported by data from the QUILT-3.032 trial, can significantly influence physician prescribing patterns and payer reimbursement decisions ahead of any formal regulatory action.

This guideline update follows a strategic regulatory move by the company. On March 9, ImmunityBio submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval for this exact papillary indication. The agency acknowledged the submission and requested additional efficacy and long-term data, but notably did not mandate new clinical trials. This is a critical detail, as papillary non-muscle invasive bladder cancer represents approximately 70% of the roughly 60,000 annual cases in the United States.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Robust Commercial Growth and a Deep Pipeline

ImmunityBio’s financial performance reflects its commercial execution. For the 2025 fiscal year, the company reported net sales of approximately $113 million for ANKTIVA, representing a year-over-year increase of about 700% driven by a 750% surge in volume. The balance sheet shows a strong position with cash, cash equivalents, and marketable securities totaling $242.8 million, alongside patent protection extending to at least 2035.

The clinical pipeline continues to advance. The first-line QUILT 2.005 study, involving 366 randomized patients, has already yielded a positive interim analysis. Results demonstrated a statistically significant improvement in response duration compared to BCG alone, with no new significant safety concerns. Additional data from this trial is expected in the fourth quarter of 2026, with a planned BLA submission to the FDA in the same quarter.

The company’s ambitions extend beyond bladder cancer. In a landmark decision, Saudi Arabia granted the world’s first conditional approval for ANKTIVA in January 2026 for use in metastatic non-small cell lung cancer in combination with checkpoint inhibitors.

A central topic for discussion at the ROTH Conference will likely be whether real-world prescribing practices and payer reimbursement in the papillary segment can keep pace with a potential future FDA label expansion. The coming months will be pivotal in shaping that trajectory.